There are currently 517 clinical trials in Lexington, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Kentucky, University of Kentucky/Markey Cancer Center, Saint Joseph Hospital East and Baptist Health Lexington. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Neurobehavioral Mechanisms of Choice in Opioid Use Disorder
NCT03958474
Recruiting
The objective of this protocol is to use probabilistic reinforcement learning choice tasks and magnetic resonance neuroimaging to demonstrate the impact of problematic opioid use and opioid withdrawal on dynamic decision-making and reveal the neurobehavioral and neurobiological processes underlying abnormal task performance. A second objective is to identify an appropriate dose of intravenous remifentanil for subsequent studies in physically dependent individuals with opioid use disorder.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/17/2025
Locations: Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky
Conditions: Opioid Use Disorder
Register for Updates
Mechanisms for Activation of Beige Adipose Tissue in Humans
NCT04666636
Recruiting
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
Gender:
ALL
Ages:
Between 35 years and 65 years
Trial Updated:
01/17/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: PreDiabetes
Register for Updates
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
NCT05051436
Recruiting
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
Gender:
ALL
Ages:
Between 35 years and 65 years
Trial Updated:
01/17/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Pre-diabetes, Obesity
Register for Updates
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
NCT03481283
Recruiting
Three pieces of information lead to the basis for this study: 1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy. 2. Increased production of the hormone amylin occurs in individuals who have Type-2 diabetes. 3. Aggregations of amylin was found in the peripheral vasculature of rats that overexpressed human amylin. The purpose of this study is to determine whether a correlation exists between the amount of amylin present in the upper extremities of human subjects with Typ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: UK Robert Straus Behavioral Science Laboratory, Lexington, Kentucky +1 locations
Conditions: Type2 Diabetes, Peripheral Neuropathy
Register for Updates
GORE® ENFORM Biomaterial Product Study
NCT04718168
Recruiting
A prospective, retrospective, non-randomized, multicenter study with two independent hernia study cohorts (Ventral / Incisional Hernia Repair and Diaphragmatic / Hiatal Hernia Repair). The primary objective of this study is to collect GORE® ENFORM Biomaterial product commercial-use data on device functional performance and short-term patient experience.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Hernia, Hiatal, Hernia, Diaphragmatic, Hernia, Ventral, Incisional Hernia
Register for Updates
Prospective Analysis of Spinal Epidural Abscess
NCT05464251
Recruiting
This is a prospective study involving all patients treated at the University of Kentucky for spinal epidural abscess over a 2-year period. Based on ongoing referrals of patients with SEA, we expect that 200 patients will be enrolled during this time window. We propose to study all available clinical, pathological, radiological, and socioeconomic data of patients diagnosed with a spinal infection with or without a history of drug abuse over this study period. All patients' charts will be prospect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Spinal Epidural Abscess
Register for Updates
Mobile Apps for Preschool Parents (MAPP) Study
NCT06520072
Recruiting
The purpose of Mobile Apps for Preschool Parents (MAPP) Study is to test the effectiveness of two mobile applications for parents of preschool aged children: 1) an app focused on child and family nutrition and wellness, and 2) an app focused on parents reading to their children.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/10/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Obesity, Childhood, Nutrition, Healthy, Physical Inactivity, Sleep, Inadequate
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Baptist Health Lexington, Lexington, Kentucky +3 locations
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
Feasibility of Implementing Time-restricted Eating in Women With Mild Cognitive Impairment
NCT05858008
Recruiting
This study will investigate the feasibility of implementing a time-restricted eating intervention in females with mild cognitive impairment. Targeted therapeutic interventions that improve cognitive impairment and delay onset of ADRD are particularly important for females, who have twice the lifetime risk of developing AD, compared to males.
Gender:
FEMALE
Ages:
Between 45 years and 95 years
Trial Updated:
01/07/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Mild Cognitive Impairment
Register for Updates
Continuous vs. Intermittent Infusion Vancomycin
NCT05823116
Recruiting
Hospitalized adult participants prescribed vancomycin by their treating physician will be randomized to receive vancomycin via continuous or intermittent infusion and measures of kidney function and injury will be collected.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Vancomycin
Register for Updates
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
NCT02915198
Recruiting
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Lexington VA Medical Center, Lexington, KY, Lexington, Kentucky
Conditions: Prediabetic State, Atherosclerosis, Metformin
Register for Updates
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049
Recruiting
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Kentucky, Markey Cancer Center, Lexington, Kentucky
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates